The stock of KemPharm Inc. (NASDAQ:KMPH) increased by increased by $0.35 on Friday to finish at $10.09, up 3.59 percent. The last five days have seen an average of 540,100 shares of common stock traded. 4 times new highs were reached in the current year, with a fall of -$1.11. The average number of shares traded over the last 20 days was 354,445, while the average volume over the last 50 days totaled 432,088.
KMPH stock appreciated 8.49% since last month. On 10/06/21, the company’s shares reached a one-month low of $8.70. The stock touched a high of $22.08 on 03/03/21, after rallying from a low of $5.07 in 52 weeks. The price of KMPH stock has declined by -9.91% or -$1.11 this year, reaching a new high 4 times. Still, the stock price is down -54.30% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
There have been 26 days since KemPharm Inc. (KMPH) last reported insider trading activity on Sep 29. On Sep 29, CFO, Secretary & Treasurer Clifton R. LaDuane acquired 215 shares at $9.38 each. This transaction resulted in the insider spending $2,017. On Sep 20, Clifton R. LaDuane added 935 shares at a price of US$8.59. After the transaction, the insider now owns 4,515 shares. CFO, Secretary & Treasurer Clifton R. LaDuane had earlier bought 230 shares on Sep 01 for $9.11 a share. The transaction was completed for $2,094.
Beta for the stock is 3.15. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 12.05, the price-to-book (PB) ratio of 2.25.
For the three months ended June 29, KemPharm Inc.’s quick ratio was 22.90, while its current ratio was 22.90, indicating its ability to pay off its debt. KemPharm Inc.’s EBITDA margin for the year ended June 29 was -33.93%, whereas its operating margin stood at -27.20% for the same period. Based on annual data, it had gross profit of $11.98 million and revenue of $13.29 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. KMPH’s return on assets (ROA) during the last 12 months has been -105.40%. There was a -242.40% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -307.70%. ROE has averaged -68.79 in the past year for the broader industry.
According to KemPharm Inc.’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $11.99 million, while revenues rose by 42.37% to $12.12 million. It was predicted that KemPharm Inc.’s quarterly earnings would be $0.21, but it ended up being $0.22, beating the consensus by -4.50%. EBITDA was $5.9 million for the quarter. At the end of KemPharm Inc.’s most recent quarter ended June 29, its liabilities totaled 8.13 million, while its total debt was $1.82 million. Equity owned by shareholders amounts to $35.15 million.
Here’s a quick look at KemPharm Inc.’s (KMPH) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 64.33%, suggesting the stock is Neutral, with a 50.36% historical volatility rate.
The stochastic %K and %D were 74.82% and 76.09% respectively, while the average true range (ATR) was 0.55. Based on the 14-day stochastic reading of 66.21%, the RSI (14) reading is 60.45%. On the 9-day MACD Oscillator, the stock is at 0.18, and the 14-day reading is at 0.50.
KemPharm Inc. (NASDAQ: KMPH) was downgraded by H.C. Wainwright to a a Neutral rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned KemPharm Inc. (KMPH) an Overweight rating. KMPH is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is KMPH’s price target for the next 12 months?
The current consensus forecast for the stock is between $10.00 and $28.00, with a median target price of $19.00. In analyzing these forecasts, the average price target given by analysts for KemPharm Inc. (KMPH) is $19.00.